The Development of Coronavirus 3C-Like Protease (3CLpro) Inhibitors from 2010 to 2020
Autor
Liu, Yuzhi
Liang, Chengyuan
Xin, Liang
Ren, Xiaodong
Tian, Lei
Ju, Xingke
Li, Han
Wang, Yongbo
Zhao, Qianqian
Liu, Hong
Cao, Wenqiang
Xie, Xiaolin
Wang, Yu
Jian, Yanlin
Institución
Resumen
3CLpro is a key enzyme for the maturation of all coronaviruses and has hence
been recognized as a potent drug target for the treatment of coronavirus infection. The
present review focuses on the status of various efficacious anti-coronavirus
small-molecule inhibitors found from various sources in the past 10 years (2010-2020)
and describes in detail the structural characteristics, binding modes and SARs of these
3CLpro inhibitors. To solve the shortcomings of “off-target” side effects and weak
inhibitory activity of existing 3CLpro inhibitors, the authors propose a new idea for
drug design, combining the emerging PROTAC technology with existing 3CLpro
inhibitors. 3CLpro PROTAC degraders are proposed as the next generation of
anti-coronavirus drugs.